Tempest Therapeutics plans first clinical study of in vivo CAR-T candidate TPST-4003 in Q4 2026

Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc.

TPST

0.00
  • Tempest Therapeutics unveiled an in vivo CAR-T platform, setting a first clinical study of lead candidate TPST-4003 for Q4 2026.
  • Investigator-initiated trial targets nervous system autoimmune diseases, initially myasthenia gravis, multiple sclerosis; about 10 patients planned.
  • First patient dosing targeted for Q4 2026; initial safety, pharmacodynamic data expected in H1 2027.
  • TPST-4003 uses CD7-targeted mRNA lipid nanoparticles to deliver a dual CD19/BCMA CAR construct previously used in TPST-2003.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150700PRIMZONEFULLFEED9762521) on July 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.